ECO Animal Health - FY Results - Investor Presentation - 16 July 2024

David Hallas (CEO) and Chris Wilks (CFO) of ECO Animal Health Group hosted an Investor Presentation covering details of FY Results (for the period to 31st March 2024).

Management highlighted adjusted EBITDA ahead of market expectations, with North America and Latin America contributing a growing share of Group revenues. The team discussed the Group's strong balance sheet with net cash at period end of £22.4m. ECO highlighted continued strong demand for Aivlosin® in key markets, particularly in the Americas, and commented on the continuing positive progress towards regulatory filing for poultry mycoplasma vaccine ECOVAXXIN®, on track for first launch in 2025. There was a wide-ranging Q&A session at the end of the presentation.

The full video is available to view, divided into chapters as below:
0:00:03 Introduction & Highlights
0:02:02 Financial highlights, including revenue progression
0:08:54 China 2022-24
0:10:31 More details on Financials
0:25:15 ESG update
0:27:13 R&D update
0:31:04 Summary & Outlook
0:31:52 Questions & Answers